(Q41653513)

6 October 2017

1 reference

title

Fluoxetine tenth anniversary update: the progress continues (English)

1 reference

6 October 2017

1 reference

Stokes PE

1

1 reference

6 October 2017

Holtz A

series ordinal

2

1 reference

6 October 2017

publication date

1 September 1997

1 reference

6 October 2017

published in

Clinical Therapeutics

1 reference

6 October 2017

volume

19

1 reference

6 October 2017

issue

5

1 reference

6 October 2017

page(s)

1135-1250

1 reference

Treatment of acute depression.

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Adequacy and duration of antidepressant treatment in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the medical outcomes study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine in tricyclic refractory major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Antidepressant specificity in atypical depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

SSRI differentiation: Pharmacology and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Clinical implications of antidepressant pharmacokinetics and pharmacogenetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Newer antidepressants and the cytochrome P450 system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The emerging role of cytochrome P450 3A in psychopharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Inhibition by fluoxetine of cytochrome P450 2D6 activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Cytochromes and psychotropic drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy black American adult subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The timing, specificity and clinical prediction of tricyclic drug effects in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Serotonin autoreceptor subsensitivity and antidepressant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Comparison of fluoxetine and desipramine in depressed outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A Multicentre Double Blind Trial of Fluoxetine versus Amitriptyline in the Treatment of Depressive Illness

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A comparison of fluvoxamine and fluoxetine in the treatment of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Moclobemide versus fluoxetine for major depressive episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Moclobemide versus fluoxetine for a major depressive episode

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Severity of depression and response to fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A comparative trial of a new antidepressant, fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A preliminary study of serotonergic antidepressants in treatment of dysthymia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Follow-up assessment of medication-treated dysthymia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Long-term treatment of double depression: a preliminary study with serotonergic antidepressants.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Moclobemide versus fluoxetine for double depression: a randomized double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Service utilization and social morbidity associated with depressive symptoms in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Depression, disability days, and days lost from work in a prospective epidemiologic survey

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The effects on performance of two antidepressants, alone and in combination with diazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

SSRIs in anxious-agitated depression: a post-hoc analysis of 279 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Predicting response to fluoxetine in geriatric patients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Assessment of quality of life in the treatment of major depressive disorder with fluoxetine, 20 mg, in ambulatory patients aged over 60 years

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Validation of the Quality of Life in Depression Scale in a population of adult depressive patients aged 60 and above.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine discontinuation in elderly dysthymic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine in elderly patients: is there cause for concern?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Antidepressant-induced hyponatraemia in the aged. Avoidance and management strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The pharmacological treatment of delusional depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The effect of sequential antidepressant treatment on geriatric depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine efficacy in treatment resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Expanding psychopharmacologic treatment options for the depressed medical patient

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The effect of fluoxetine on anxiety and depression symptoms in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Poststroke depression and fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Structured group therapy and fluoxetine to treat depression in HIV-positive persons

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Moclobemide and fluoxetine in atypical depression: a double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

An open naturalistic trial of fluoxetine in adolescents and young adults with treatment-resistant major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Subgroups of adolescent depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Elective mutism: an analysis of 100 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Psychopathology and plasma cortisol responses to dexamethasone in prepubertal psychiatric inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine in obsessive compulsive disorder in adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine for adolescents with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Methamphetamine and fluoxetine treatment of a child with attention-deficit hyperactivity disorder and obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine for childhood anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine in anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Comorbidity of parental anxiety disorders as risk for childhood-onset anxiety in inhibited children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A 3-year follow-up of children with and without behavioral inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Pharmacotherapy of the eating disorders: a commentary

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Pharmacotherapy of bulimia nervosa--experience with fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Effects of fluoxetine on the oral environment of bulimics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa--restricted type.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 2. Anorexia nervosa--binge-eating/purging type.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Obsessive-compulsive disorder, trichotillomania, and anorexia nervosa: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Clinical studies with fluoxetine in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A study of fluoxetine in obese elderly patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

One-month prevalence of mental disorders in the United States and sociodemographic characteristics: the Epidemiologic Catchment Area study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Serotonergic drugs in trichotillomania: treatment results in 12 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Early nonresponse to fluoxetine as a predictor of poor 8-week outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Use of pattern analysis to identify true drug response. A replication

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Possible synergism between fluoxetine and lithium in refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Refractory depression: the addition of lithium to fluoxetine or desipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Serotonin syndrome produced by a combination of fluoxetine and lithium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Effectiveness of Pindolol With Selected Antidepressant Drugs in the Treatment of Major Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Buspirone augmentation of fluoxetine in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Dexamethasone augmentation in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Withdrawal syndromes after paroxetine and sertraline discontinuation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Serotonin reuptake inhibitor withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Male Sexual Side Effects Associated with Antidepressants: A Descriptive Clinical Study of 32 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine-induced sexual dysfunction: a dose-dependent effect?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin re-uptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Management of poisoning associated with "newer" antidepressant agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Comparative safety and tolerability of selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Do SSRIs differ in their antidepressant efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Safety of mirtazapine: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Bruising associated with the use of fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Adverse vascular effects associated with fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Subhyaloid haemorrhage with fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine and bleeding in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Bleeding, a side effect of fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Effects of serotonin reuptake inhibitors on hemostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine-warfarin interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The effect of fluoxetine on warfarin metabolism in the rat and man

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Risk factors for the development of hyponatremia in psychiatric inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Extrapyramidal symptoms with selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine and extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Potential withdrawal syndrome associated with SSRI discontinuation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Physical symptoms associated with paroxetine discontinuation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Severe psychiatric symptoms associated with paroxetine withdrawal.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Paroxetine induced withdrawal effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

A possible paroxetine withdrawal syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Paroxetine withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Is there a serotonergic withdrawal syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Extrapyramidal symptoms upon discontinuation of fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine withdrawal?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

In utero exposure to fluoxetine HCl increases hematoma frequency at birth

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Effects of serotonin uptake inhibitor, Lilly 110140, on transport of serotonin in rat and human blood platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Birth outcomes in pregnant women taking fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Neurodevelopment of children exposed in utero to antidepressant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

CONGENITAL ANOMALIES IN THE NEWBORN INFANT, INCLUDING MINOR VARIATIONS. A STUDY OF 4,412 BABIES BY SURFACE EXAMINATION FOR ANOMALIES AND BUCCAL SMEAR FOR SEX CHROMATIN

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Predictive value of minor anomalies. I. Association with major malformations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Effects of third trimester fluoxetine exposure on the newborn

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Pregnancy and birth complications among mentally ill and well mothers and their children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine distribution in human milk

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Possible association between fluoxetine hydrochloride and colic in an infant.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Antidepressant treatment during breast-feeding

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The safety of antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine overdose: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Report of a fluoxetine fatality

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Acute fluoxetine overdose: a report of 234 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Seizure after isolated fluoxetine overdose.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Relative mortality from overdose of antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Suicide and Primary Affective Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Seriousness of suicide attempt in relation to personality

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Suicide Rates in the Lundby Study: Mental Illness as a Risk Factor for Suicide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The Emergence of Suicidal Ideation and Behavior During Antidepressant Pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Emergence of intense suicidal preoccupation during fluoxetine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine and suicidal behaviour. Some clinical and theoretical aspects of a controversy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The influence of fluoxetine on aggressive behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Fluoxetine Not Associated With Increased Violence or Aggression in Controlled Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Anger attacks in unipolar depression, Part 1: Clinical correlates and response to fluoxetine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Alcoholism and suicide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Alcohol and Central Serotonin Metabolism in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Biochemical markers in suicidal patientsInvestigations with cerebrospinal fluid amine metabolites and neuroendocrine tests

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Regional brain levels of monoamines in alcohol-preferring and -nonpreferring lines of rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Ethanol interactions with serotonin uptake selective and non-selective antidepressants: Fluoxetine and amitriptyline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Differential costs of treatment of depression with SSRIs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

The added costs of depression to medical care

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Depression and somatization: a review. Part I.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Depression and somatization: a review. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Treating depression and anxiety in primary care. Closing the gap between knowledge and practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Disability and depression among high utilizers of health care. A longitudinal analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Recognition of depression by internists in primary care: a comparison of internist and "gold standard" psychiatric assessments

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

An experiment to change detection and management of mental morbidity in primary care.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Recognition, management, and outcomes of depression in primary care.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Association of symptoms of depression with diagnostic test charges among older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Pharmacokinetics of the newer antidepressants: clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Recent pharmacologic advances in antidepressant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

First-episode major depression. Few sex differences in course.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

Recent developments in the pharmacotherapy of mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980066-5

7 January 2021

10.1016/S0149-2918(97)80066-5

Identifiers

DOI

1 reference

6 October 2017

1 reference